Global health is suffering from hospital-acquired infections (HAI), exacerbated by antimicrobial resistance (AMR). BioPlx. Inc. is dedicated to preventing HAI, which threatens preventative and curative measures for deadly infectious diseases. They create unique microbiome-embedded prokaryotic formulations that function as targeted therapeutic agents. This innovative biotechnology uses bacterial interference and niche dynamics strategies to achieve durable microbiome integration, and proprietary molecular methods to functionally enhance its therapeutic organisms. Their product BioPlx SafeShieldTM is a kill switch enhanced technology that prevents the occurrence and recurrence of colonization, while improving patient health, helping to reduce financial burdens, and slowing the advancement of AMR.